Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.

Maxime Luu 1, 2 Marc Bardou 1, 2, 3 Philippe Bonniaud 1, 4 Françoise Goirand 1, 5, *
* Auteur correspondant
2 PIT - Plateforme d’Investigation Technologique [Centre d’Investigation Clinique 1432 module Plurithématique - Dijon]
CAPS - Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093], CIC-P803 - Centre d'Investigation Clinique 1432 (Dijon) - Module Plurithématique : Périnatalité Cancérologie Handicap et Ophtalmologie
Abstract : Omalizumab is a subcutaneously administrated monoclonal anti-IgE antibody indicated in adults, adolescents and children 6 years of age and older with moderate to severe allergic asthma uncontrolled by conventional pharmacological treatments and sensitization to at least one perennial allergen. Area covered: This drug evaluation summarizes published data on pharmacokinetic and pharmacodynamic properties of omalizumab, on clinical efficacy and safety, including real-world evidence, and provides a medico-economic evaluation of the drug. Expert opinion: Omalizumab represents an efficient therapeutic option for the management of patients with uncontrolled moderate/severe allergic asthma. It provides a significant reduction in the asthma exacerbation rate with a steroid-sparing effect, an improvement in quality of life in adults and adolescents, despite a lack of evidence about its efficacy specifically in severe allergic asthma. Clinical trials have demonstrated its efficacy in the pediatric population but further real-life evidence is expected to better characterize long-term effects in this population. There is still some debate about the optimal treatment duration but, to date, it is recommended not to stop the treatment as cessation has resulted in symptom recurrence. Omalizumab is an expensive treatment, but a key therapeutic option when used for uncontrolled severe allergic asthma.
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01430556
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : mardi 10 janvier 2017 - 09:24:19
Dernière modification le : vendredi 8 juin 2018 - 14:50:25

Identifiants

Citation

Maxime Luu, Marc Bardou, Philippe Bonniaud, Françoise Goirand. Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.. Expert Opinion on Drug Metabolism and Toxicology, Taylor & Francis, 2016, 12 (12), pp.1503-1511. ⟨http://www.tandfonline.com/doi/abs/10.1080/17425255.2016.1248403?journalCode=iemt20⟩. ⟨10.1080/17425255.2016.1248403⟩. ⟨hal-01430556⟩

Partager

Métriques

Consultations de la notice

247